Patents by Inventor James H. Lee
James H. Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230183397Abstract: The present invention relates to the polymerisation of one or more monomers in a gas phase reactor, and in particular provides a process for from the polymerisation of one or more monomers in a horizontal stirred bed gas phase reactor, wherein the process comprises: a. Polymerising a mixture comprising one or more monomers and hydrogen in the reactor to produce the polymer, b. Withdrawing from the reactor a gaseous stream, c. Passing the gaseous stream to a condenser in which it is partly condensed to produce a liquid phase and a remaining vapour phase, d. Passing the mixture of liquid phase and remaining vapour from the condenser to a separator in which there is maintained a liquid phase and a vapour phase, the volume of the liquid phase in the separator being a percentage, X, which is between 10 and 80% of the total volume of the separator, e.Type: ApplicationFiled: December 9, 2021Publication date: June 15, 2023Inventors: William E. BEARDSLEY, Robert TOPLISS, James H. LEE, William D. STEPHENS
-
Publication number: 20220296224Abstract: A system, assembly, or method for the acute delivery of medications or fluids to a surface such as the eye includes a rod coupled to an absorbent material. The rod and the absorbent material may be advanced through a casing to be delivered to a patient's tissue.Type: ApplicationFiled: April 30, 2020Publication date: September 22, 2022Inventor: James H. Lee
-
Patent number: 10127658Abstract: Disclosed are apparatus and methods determining a center offset distance for computed tomography imaging. A specimen is positioned between an emission source for outputting radiation towards the specimen while the specimen rotates with respect to a detector for receiving radiation that has passed through the specimen. Projection data is collected from emissions received at the detector for multiple rotational positions of the specimen. A sinogram image is generated based on the projection data. The sinogram image is divided into image portions, which are superimposed and iteratively moved relative to each other by a relative offset so that a superimposed image peak in such superimposed image portions has a maximized height. A center offset distance for the sinogram image is defined as a relative offset between the superimposed image portions that results in the maximized height.Type: GrantFiled: November 21, 2016Date of Patent: November 13, 2018Assignee: The Boeing CompanyInventor: James H. Lee
-
Patent number: 10127691Abstract: Disclosed are apparatus and methods determining a center offset distance for computed tomography (CT) imaging. A specimen is positioned between an emission source for outputting radiation towards the specimen while the specimen rotates with respect to a detector for receiving radiation that has passed through the specimen. A center calibration indicator (CCI) is also positioned near the specimen so that at least a portion of the radiation passes through the CCI onto the detector. Projection data is collected from emissions received at the detector for multiple rotational positions of the specimen relative to the detector. A sinogram image is generated based on the projection data. Two alignment points corresponding to the CCI are located in the sinogram and used to determine the center offset distance for the sinogram. A specimen image is reconstructed by back projecting the sinogram using the determined center offset distance.Type: GrantFiled: November 21, 2016Date of Patent: November 13, 2018Assignee: The Boeing CompanyInventor: James H. Lee
-
Publication number: 20180144511Abstract: Disclosed are apparatus and methods determining a center offset distance for computed tomography (CT) imaging. A specimen is positioned between an emission source for outputting radiation towards the specimen while the specimen rotates with respect to a detector for receiving radiation that has passed through the specimen. A center calibration indicator (CCI) is also positioned near the specimen so that at least a portion of the radiation passes through the CCI onto the detector. Projection data is collected from emissions received at the detector for multiple rotational positions of the specimen relative to the detector. A sinogram image is generated based on the projection data. Two alignment points corresponding to the CCI are located in the sinogram and used to determine the center offset distance for the sinogram. A specimen image is reconstructed by back projecting the sinogram using the determined center offset distance.Type: ApplicationFiled: November 21, 2016Publication date: May 24, 2018Applicant: The Boeing CompanyInventor: James H. Lee
-
Publication number: 20180144462Abstract: Disclosed are apparatus and methods determining a center offset distance for computed tomography imaging. A specimen is positioned between an emission source for outputting radiation towards the specimen while the specimen rotates with respect to a detector for receiving radiation that has passed through the specimen. Projection data is collected from emissions received at the detector for multiple rotational positions of the specimen. A sinogram image is generated based on the projection data. The sinogram image is divided into image portions, which are superimposed and iteratively moved relative to each other by a relative offset so that a superimposed image peak in such superimposed image portions has a maximized height. A center offset distance for the sinogram image is defined as a relative offset between the superimposed image portions that results in the maximized height.Type: ApplicationFiled: November 21, 2016Publication date: May 24, 2018Applicant: The Boeing CompanyInventor: James H. Lee
-
Patent number: 9370509Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.Type: GrantFiled: August 6, 2012Date of Patent: June 21, 2016Assignee: Medicis Pharmaceutical CorporationInventors: Michael T. Nordsiek, Sharon F. Levy, James H. Lee, James H. Kulp, Kodumudi S. Balaji, Tze-Chiang Meng, Jason J. Wu, Valyn S. Bahm, Robert Babilon
-
Patent number: 8946274Abstract: Methods of improving skin quality are disclosed. Generally, the methods include topically administering an IRM compound to a treatment area of skin for a period of time and in an amount effective for improving the quality of the skin. Suitable IRM compound compounds include agonists of one or more TLRs.Type: GrantFiled: September 10, 2012Date of Patent: February 3, 2015Assignee: Medicis Pharmaceutical CorporationInventors: Richard L. Miller, James H. Lee, Mary L. Owens
-
Publication number: 20130210855Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.Type: ApplicationFiled: August 6, 2012Publication date: August 15, 2013Applicant: MEDICIS PHARMACEUTICAL CORPORATIONInventors: Michael T. NORDSIEK, Sharon F. LEVY, James H. LEE, James H. KULP, Kodumudi S. BALAJI, Tze-Chiang MENG, Jason J. WU, Valyn S. BAHM, Robert BABILON
-
Publication number: 20130149341Abstract: Methods of improving skin quality are disclosed. Generally, the methods include topically administering an IRM compound to a treatment area of skin for a period of time and in an amount effective for improving the quality of the skin. Suitable IRM compound compounds include agonists of one or more TLRs.Type: ApplicationFiled: September 10, 2012Publication date: June 13, 2013Applicant: Medicis Pharmaceutical CorporationInventors: Richard L. Miller, James H. Lee, Mary L. Owens
-
Patent number: 8426457Abstract: Methods of improving skin quality are disclosed. Generally, the methods include topically administering an IRM compound to a treatment area of skin for a period of time and in an amount effective for improving the quality of the skin. Suitable IRM compound compounds include agonists of one or more TLRs.Type: GrantFiled: March 12, 2004Date of Patent: April 23, 2013Assignee: Medicis Pharmaceutical CorporationInventors: Richard L. Miller, James H. Lee, Mary L. Owens
-
Patent number: 8354424Abstract: A method of treating actinic keratosis including applying topically to an actinic keratosis lesion twice per week for a duration of 8 weeks a formulation comprising 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine.Type: GrantFiled: March 14, 2006Date of Patent: January 15, 2013Assignee: Medicis Pharmaceutical CorporationInventors: James H. Lee, Terrance L. Fox
-
Publication number: 20120329825Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2 methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.Type: ApplicationFiled: July 26, 2012Publication date: December 27, 2012Applicant: MEDICIS PHARMACEUTICAL CORPORATIONInventors: Michael T. NORDSIEK, Sharon F. LEVY, James H. LEE, James H. KULP, Kodumudi S. BALAJI, Tze-Chiang MENG, Jason J. WU, Valyn S. BAHM, Robert BABILON
-
Publication number: 20120329824Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.Type: ApplicationFiled: July 26, 2012Publication date: December 27, 2012Applicant: MEDICIS PHARMACEUTICAL CORPORATIONInventors: Michael T. NORDSIEK, Sharon F. LEVY, James H. LEE, James H. KULP, Kodumudi S. BALAJI, Tze-Chiang MENG, Jason J. WU, Valyn S. BAHM, Robert BABILON
-
Publication number: 20120329823Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.Type: ApplicationFiled: June 26, 2012Publication date: December 27, 2012Applicant: Medicis Pharmaceutical CorporationInventors: Michael T. Nordsiek, Sharon F. Levy, James H. Lee, James H. Kulp, Kodumudi S. Balaji, Tze-Chiang Meng, Jason J. Wu, Valyn S. Bahm, Robert Babilon
-
Publication number: 20120289538Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.Type: ApplicationFiled: July 26, 2012Publication date: November 15, 2012Applicant: MEDICIS PHARMACEUTICAL CORPORATIONInventors: Michael T. NORDSIEK, Sharon F. LEVY, James H. LEE, James H. KULP, Kodumudi S. BALAJI, Tze-Chiang MENG, Jason J. WU, Valyn S. BAHM, Robert BABILON
-
Patent number: 8299109Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available ALDARA 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for ALDARA 5% imiquimod cream to treat actinic keratosis are also disclosed and described.Type: GrantFiled: July 13, 2011Date of Patent: October 30, 2012Assignee: Medicis Pharmaceutical CorporationInventors: Michael T. Nordsiek, Sharon F. Levy, James H. Lee, James H. Kulp, Kodumudi S. Balaji, Tze-Chiang Meng, Jason J. Wu, Valyn S. Bahm, Robert Babilon
-
Patent number: 8242155Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available ALDARA 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for ALDARA 5% imiquimod cream to treat actinic keratosis are also disclosed and described.Type: GrantFiled: July 13, 2011Date of Patent: August 14, 2012Assignee: Medicis Pharmaceutical CorporationInventors: Michael T. Nordsiek, Sharon F. Levy, James H. Lee, James H. Kulp, Kodumudi S. Balaji, Tze-Chiang Meng, Jason J. Wu, Valyn S. Bahm, Robert Babilon
-
Patent number: 8236816Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available ALDARA 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for ALDARA 5% imiquimod cream to treat actinic keratosis are also disclosed and described.Type: GrantFiled: July 12, 2011Date of Patent: August 7, 2012Assignee: Medicis Pharmaceutical CorporationInventors: Michael T. Nordsiek, Sharon F. Levy, James H. Lee, James H. Kulp, Kodumudi S. Balaji, Tze-Chiang Meng, Jason J. Wu, Valyn S. Bahm, Robert Babilon
-
Patent number: D816571Type: GrantFiled: May 27, 2016Date of Patent: May 1, 2018Assignee: HONDA MOTOR CO., LTD.Inventors: Michael Wiedeman, James H Lee